DL
HZNP

Daniel Loeb’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Daniel Loeb’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-500,000
Closed -$51.4M – 54
2023
Q2 		$51.4M Buy
+500,000
New +$52.8M 0.75% 27

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Daniel Loeb's HZNP Position: Q3 2023 in Review

Daniel Loeb sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2023, closing a stake of 500,000 shares — an estimated $51.4M sold.

Daniel Loeb first reported a position in HZNP in Q2 2023 and held it in 1 quarter. The position peaked at $51.4M in Q2 2023. 485 funds tracked by Wall St. Rank hold HZNP as of Q3 2023.

  • Daniel Loeb reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2023 after selling out during the quarter.
  • Daniel Loeb sold 500,000 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2023, an estimated $51.4M.
  • Daniel Loeb first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2023 and held it in 1 quarter.
  • Daniel Loeb's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $51.4M in Q2 2023.
  • 485 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2023.

Based on Third Point's 13F filing for Q3 2023, filed 14 Nov 2023.